Effects of captopril on atherosclerosis in cynomolgus monkeys.
A study was performed to investigate if oral dosing of captopril could influence the development of atherosclerosis in cholesterol-fed cynomolgus monkeys. Twenty-four monkeys were divided into four groups: (a) a control group given a normal monkey diet and placebo medication; (b) a high cholesterol group given a high cholesterol diet and placebo medication; (c) a low-dose captopril group given the cholesterol diet and 25 mg/kg of captopril twice daily; and (d) a high-dose captopril group given the cholesterol diet and 50 mg/kg of captopril twice daily. The doses of captopril used in this study did not change the levels of total serum cholesterol, high-density lipoprotein (HDL), or triglycerides. The total cholesterol/HDL ratio was also unaffected by captopril. The animals were killed after 6 months of treatment. The progression of atherosclerosis was assessed by gross pathology, histopathology, and biochemical methods. The results showed a significantly reduced progression of arterial lesions in monkeys given captopril; the effects of captopril were most evident in the coronary arteries, which were practically free from atherosclerosis in captopril-treated animals.
Department of Pharmacology, Squibb Institute for Medical Research, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000.
G
G
Aberg
P
P
Ferrer
D000818:Animals; D001011:Aorta / Q000473:pathology; D001161:Arteriosclerosis / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D001794:Blood Pressure / Q000187:drug effects; D002216:Captopril / Q000097:blood / Q000627:therapeutic use*; D002339:Carotid Arteries / Q000473:pathology; D002784:Cholesterol / Q000097:blood / Q000378:metabolism; D004036:Diet, Atherogenic; D007083:Iliac Artery / Q000473:pathology; D008055:Lipids / Q000097:blood; D008252:Macaca fascicularis; D008297:Male; D009206:Myocardium / Q000473:pathology
D008055:Lipids; D002784:Cholesterol; D002216:Captopril